Department of Oral Diagnostic Sciences, Faculty of Dentistry, Prince of Songkla University, Hat-Yai, 90112, Thailand.
Common Oral Diseases and Epidemiology Research Center, Hat-Yai, Thailand.
Probiotics Antimicrob Proteins. 2023 Oct;15(5):1137-1150. doi: 10.1007/s12602-022-09972-y. Epub 2022 Jul 27.
This study aimed to characterize the anti-cancer properties of potential probiotics (Lacticaseibacillus paracasei SD1, Lacticaseibacillus rhamnosus SD4, Lacticaseibacillus rhamnosus SD11, and Lacticaseibacillus rhamnosus GG) and their cell-free supernatants (CFS) for the prevention of colorectal cancer (CRC), which including anti-bacterial and anti-inflammation activities against pathogens associated with CRC (Fusobacterium nucleatum, Porphyromonas gingivalis, ETEC, and Salmonella enterica). The expression of human β-defensin (2-4) and IL-10 after being stimulated with probiotics was also examined. In addition, anti-cancer activity of CFS and probiotic growth under intestinal conditions were determined. An in vitro study was conducted in the Caco-2 and HIEC-6 cells. Results showed that probiotic cells and their CFS displayed different antibacterial activity, and L. rhamnosus SD11 showed the strongest inhibition of the growth of pathogens. Additionally, both probiotic cell walls and their CFS suppressed pro-inflammatory cytokines after being stimulated with pathogens in Caco-2 and HIEC-6 cells. L. paracasei SD1 and L. rhamnosus SD11 showed significantly higher suppression levels than others and also both strains can stimulate highly expression of hBD (2-4) and IL-10. The CFS of L. paracasei SD1 and L. rhamnosus SD11 inhibited significantly high growth of Caco-2 cells but not much in HIEC-6 cells. Furthermore, all probiotics adhered to Caco-2 and HIEC-6 cells, and L. rhamnosus SD4 showed the highest adhesion to both cells. They could survive more than 70% in intestinal conditions. In conclusion, results indicate that potential probiotics tested exhibited various anti-cancer properties, which may be good candidates used as biotherapy for the prevention or to delay the progression of CRC.
本研究旨在表征潜在益生菌（副干酪乳杆菌 SD1、鼠李糖乳杆菌 SD4、鼠李糖乳杆菌 SD11 和鼠李糖乳杆菌 GG）及其无细胞上清液（CFS）的抗癌特性，以预防结直肠癌（CRC），包括对与 CRC 相关的病原体（具核梭杆菌、牙龈卟啉单胞菌、肠致病性大肠杆菌和肠炎沙门氏菌）的抗菌和抗炎活性。还研究了益生菌刺激后人类β-防御素（2-4）和 IL-10 的表达。此外，还测定了 CFS 和益生菌在肠道条件下的抗癌活性。在 Caco-2 和 HIEC-6 细胞中进行了体外研究。结果表明，益生菌细胞及其 CFS 表现出不同的抗菌活性，而 SD11 显示出对病原体生长最强的抑制作用。此外，益生菌细胞壁及其 CFS 在 Caco-2 和 HIEC-6 细胞中被病原体刺激后均能抑制促炎细胞因子的产生。与其他菌株相比，SD1 和 SD11 这两种菌株都能显著提高 hBD（2-4）和 IL-10 的表达水平。SD1 和 SD11 的 CFS 能显著抑制 Caco-2 细胞的生长，但对 HIEC-6 细胞的抑制作用不大。此外，所有益生菌都能黏附在 Caco-2 和 HIEC-6 细胞上，而 SD4 对这两种细胞的黏附性最高。它们在肠道条件下的存活率超过 70%。总之，结果表明，所测试的潜在益生菌表现出多种抗癌特性，可能是作为 CRC 预防或延缓进展的生物治疗的良好候选物。
